Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.2700
-0.0051 (-1.85%)
At close: Apr 16, 2026, 4:00 PM EDT
0.2729
+0.0029 (1.07%)
After-hours: Apr 16, 2026, 6:31 PM EDT
Sangamo Therapeutics Employees
Sangamo Therapeutics had 142 employees as of December 31, 2025. The number of employees decreased by 41 or -22.40% compared to the previous year.
Employees
142
Change (1Y)
-41
Growth (1Y)
-22.40%
Revenue / Employee
$278,535
Profits / Employee
-$865,718
Market Cap
111.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 142 | -41 | -22.40% |
| Dec 31, 2024 | 183 | -222 | -54.81% |
| Dec 31, 2023 | 405 | -73 | -15.27% |
| Dec 31, 2022 | 478 | 47 | 10.90% |
| Dec 31, 2021 | 431 | 18 | 4.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Pyxis Oncology | 56 |
| Equillium | 35 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
| AN2 Therapeutics | 21 |
| Aldeyra Therapeutics | 8 |
SGMO News
- 17 days ago - Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - GlobeNewsWire
- 5 weeks ago - Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 5 months ago - Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - GlobeNewsWire